156 related articles for article (PubMed ID: 200243)
1. A selective thromboxane synthetase inhibitor blocks the cAMP lowering activity of PGH2.
Gorman RR; Fitzpatrick FA; Miller OV
Biochem Biophys Res Commun; 1977 Nov; 79(1):305-13. PubMed ID: 200243
[No Abstract] [Full Text] [Related]
2. Thromboxane synthetase inhibitors as pharmacological tools: differential biochemical and biological effects on platelet suspensions.
Needleman P; Bryan B; Wyche A; Bronson SD; Eakins K; Ferrendelli JA; Minkes M
Prostaglandins; 1977 Nov; 14(5):897-907. PubMed ID: 594391
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of human platelet thromboxane synthetase by 9,11-azoprosta-5,13-dienoic acid.
Gorman RR; Bundy GL; Peterson DC; Sun FF; Miller OV; Fitzpatrick FA
Proc Natl Acad Sci U S A; 1977 Sep; 74(9):4007-11. PubMed ID: 269449
[TBL] [Abstract][Full Text] [Related]
4. Prostaglandin H2 directly lowers human platelet cAMP levels.
Rybicki JP; Le Breton GC
Thromb Res; 1983 Jun; 30(5):407-14. PubMed ID: 6310815
[TBL] [Abstract][Full Text] [Related]
5. A comparison of imidazole and 9,11-azoprosta-5,13-dienoic acid. Two selective thromboxane synthetase inhibitors.
Fitzpatrick FA; Gorman RR
Biochim Biophys Acta; 1978 Mar; 539(2):162-72. PubMed ID: 629996
[TBL] [Abstract][Full Text] [Related]
6. Synergistic activation by collagen and 15-hydroxy-9 alpha,11 alpha-peroxidoprosta-5,13-dienoic acid (PGH2) of phosphatidylinositol metabolism and arachidonic acid release in human platelets.
Rittenhouse SE; Allen CL
J Clin Invest; 1982 Dec; 70(6):1216-24. PubMed ID: 6816811
[TBL] [Abstract][Full Text] [Related]
7. Lag-phase of arachidonic acid-induced secretion in responders and non-responders to the thromboxane-synthetase inhibitors: involvement of cyclic-AMP.
Lecompte T; Joussemet M; Hainaut J
Thromb Res; 1984 Jul; 35(1):91-7. PubMed ID: 6089368
[No Abstract] [Full Text] [Related]
8. Biochemical and pharmacological evaluation of thromboxane synthetase inhibitors.
Gorman RR
Adv Prostaglandin Thromboxane Res; 1980; 6():417-25. PubMed ID: 6247892
[No Abstract] [Full Text] [Related]
9. Characterization of thromboxane receptors in human platelets.
Jones RL; Wilson NH; Armstrong RA
Adv Exp Med Biol; 1985; 192():67-81. PubMed ID: 3010674
[No Abstract] [Full Text] [Related]
10. Manipulation of platelet aggregation by prostaglandins and their fatty acid precursors: pharmacological basis for a therapeutic approach.
Needleman P; Whitaker MO; Wyche A; Watters K; Sprecher H; Raz A
Prostaglandins; 1980 Jan; 19(1):165-81. PubMed ID: 6247744
[TBL] [Abstract][Full Text] [Related]
11. Competitive antagonism at thromboxane receptors in human platelets.
Armstrong RA; Jones RL; Peesapati V; Will SG; Wilson NH
Br J Pharmacol; 1985 Mar; 84(3):595-607. PubMed ID: 2580580
[TBL] [Abstract][Full Text] [Related]
12. Prostaglandins and human platelet aggregation. Implications for the anti-aggregating activity of thromboxane-synthase inhibitors.
Rajtar G; Cerletti C; Castagnoli MN; Bertelé V; de Gaetano G
Biochem Pharmacol; 1985 Feb; 34(3):307-10. PubMed ID: 3918536
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of 9,11-azo-13-oxa-15-hydroxyprostanoic acid, a potent inhibitor of platelet aggregation.
Kam ST; Portoghese PS; Gerrard JM; Dunham EW
J Med Chem; 1979 Nov; 22(11):1402-8. PubMed ID: 533888
[TBL] [Abstract][Full Text] [Related]
14. Arachidonic acid induces human platelet-fibrin retraction: the role of platelet cyclic endoperoxides.
Di Minno G; Bertelé V; Cerletti C; de Gaetano G; Silver MJ
Thromb Res; 1982 Feb; 25(4):299-306. PubMed ID: 6803385
[TBL] [Abstract][Full Text] [Related]
15. Effects of OKY 1581 on bronchoconstrictor responses to arachidonic acid and PGH2.
Tilden SJ; Underwood DC; Cowen KH; Wegmann MJ; Graybar GB; Hyman AL; McNamara DB; Kadowitz PJ
J Appl Physiol (1985); 1987 May; 62(5):2066-74. PubMed ID: 2954941
[TBL] [Abstract][Full Text] [Related]
16. Reversal of thromboxane A2/prostaglandin H2 and ADP-induced calcium release in intact platelets.
Brace LD; Venton DL; Le Breton GC
Am J Physiol; 1985 Jul; 249(1 Pt 2):H8-13. PubMed ID: 2409821
[TBL] [Abstract][Full Text] [Related]
17. Prostaglandin H2 in human platelet activation: coactivator and substitute for thromboxane A2.
Hornberger WB; Patscheke H
Prog Clin Biol Res; 1989; 301():315-9. PubMed ID: 2798452
[TBL] [Abstract][Full Text] [Related]
18. Partial agonism of prostaglandin H2 analogs and 11-deoxy-prostaglandin F2 alpha to thromboxane-sensitive preparations.
Jones RL; Wilson NH
Adv Prostaglandin Thromboxane Res; 1980; 6():467-75. PubMed ID: 7386280
[No Abstract] [Full Text] [Related]
19. Triene prostaglandins: prostaglandin D3 and icosapentaenoic acid as potential antithrombotic substances.
Whitaker MO; Wyche A; Fitzpatrick F; Sprecher H; Needleman P
Proc Natl Acad Sci U S A; 1979 Nov; 76(11):5919-23. PubMed ID: 230492
[TBL] [Abstract][Full Text] [Related]
20. Thromboxane A2/prostaglandin H2 mobilizes calcium in human blood platelets.
Brace LD; Venton DL; Le Breton GC
Am J Physiol; 1985 Jul; 249(1 Pt 2):H1-7. PubMed ID: 3925795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
